EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure

Fumihiro Ito iD, Koki Kobayashi, Gaku Hayashi iD, Shunsuke Kamijo iD, Takashi Fujita iD

IJU Case Reports · 2026-11 · 9 (6)

DOI: 10.1002/iju5.70276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 27.09.2026. Verfasst von Fumihiro Ito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Urachal carcinoma is a rare and aggressive malignancy with no established systemic therapy after platinum failure. Evidence for immune checkpoint inhibitors (ICIs) remains limited, particularly in tumors without established favorable biomarkers such as microsatellite instability‐high status or high tumor mutational burden. Case Presentation A 55‐year‐old woman with metastatic urachal adenocarcinoma progressed after seven cycles of gemcitabine–cisplatin. Pembrolizumab (200 mg every three weeks) was initiated, resulting in a durable partial response lasting over 12 months without immune‐related adverse events. Molecular profiling showed microsatellite stability, low tumor mutational burden, and insufficient tissue for (Programmed death‐ligand 1) PD‐L1 assessment.

Conclusion

This case demonstrates durable disease control with pembrolizumab in metastatic urachal carcinoma despite microsatellite stability and low tumor mutational burden. These findings suggest the potential efficacy of pembrolizumab in selected patients with platinum‐refractory disease.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorpelvic lymph node metastasispembrolizumabplatinum chemotherapyurachal carcinoma

Autor:innen und Institutionen

  • Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan.

ORCID-Profile: Fumihiro Ito, Gaku Hayashi, Shunsuke Kamijo, Takashi Fujita

Zitieren

APA

Ito, F., Kobayashi, K., Hayashi, G., Kamijo, S., & Fujita, T. (2026). Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure. IJU Case Reports, 9(6). https://doi.org/10.1002/iju5.70276

Vancouver

Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T. Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure. IJU Case Reports. 2026;9(6). doi:10.1002/iju5.70276

BibTeX
@article{Ito2026,
  author = {Ito, Fumihiro and Kobayashi, Koki and Hayashi, Gaku and Kamijo, Shunsuke and Fujita, Takashi},
  title = {Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {6},
  doi = {10.1002/iju5.70276}
}
Kostenlos starten →